SynthesisFrontiers in nutrition2025
Long-term impact of sarcopenia on functional decline and mortality in community-dwelling older adults: a systematic review and meta-analysis.
Synthesis in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia is an age-related syndrome characterized by progressive loss of muscle mass and function. While it is considered a key predictor of adverse health outcomes, comprehensive evidence regarding its long-term impact on functional decline and mortality in community-dwelling older adults remains limited. Objective: To evaluate the longitudinal association between baseline sarcopenia and risks of functional decline and all-cause mortality among community-dwelling older adults, with subgroup analyses based on methods of sarcopenia assessment and domains of functional decline. Methods: We conducted a systematic review and meta-analysis following PRISMA 2020 and MOOSE guidelines. Seven databases were searched from inception to September 30 Results: A total of 39 studies involving 76151 participants were included. Sarcopenia was significantly associated with an increased risk of all-cause mortality (29 publications, OR = 1.79, 95%CI: 1.55~2.06) and functional decline (16 publications, OR = 1.90, 95%CI: 1.55~2.32). Subgroup analyses revealed consistent associations across different muscle mass assessment methods (DXA, BIA, and CT). Notably, sarcopenia was associated with both physical (OR = 1.91, 95%CI: 1.52~2.40) and cognitive/psychological functional decline (OR = 2.03, 95%CI: 1.35~3.05). Heterogeneity was moderate to high but did not substantially alter the results in sensitivity analyses. Conclusion: This meta-analysis confirms that sarcopenia significantly predicts long-term functional decline and mortality in community-dwelling older adults, with robust associations across multiple muscle mass measurement methods and functional domains. These findings highlight the importance of standardized sarcopenia screening and early intervention to mitigate long-term functional impairment and mortality risk in aging populations. Clinical trial registration: PROSPERO (ID CRD42024595362).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.